RCC

Oncology

Prevalence

30.0 / 100K

21 drugs in development·14 companies·1 clinical trial

Drug Pipeline by Phase

Approved(6)

Phase 3(5)

Phase 1(6)

Drug	Company
ADI-270	Adicet Bio, Inc. (ACET)
arx305	Ambrx Biopharma Cayman, Inc. (AMAM)
ciforadenant	Corvus Pharmaceuticals, Inc. (CRVS)
epacadostat	Incyte Corp. (INCY)
ko-2806	Kura Oncology, Inc. (KURA)
Temferon	Royalty Pharma plc (RPRX)

Preclinical(2)

Drug	Company
anti-caix	Checkpoint Therapeutics, Inc. (CKPT)
anti-caix antibody	Checkpoint Therapeutics, Inc. (CKPT)

Phase 1/Phase 2(2)

Drug	Company
cabozantinib	Genenta Science S.p.A. (GNTA)
temferon	Genenta Science S.p.A. (GNTA)

BioSniper tracks 21 drugs in development for RCC across 14 companies.

There are 1 clinical trial targeting RCC tracked by BioSniper.

The estimated prevalence of RCC is approximately 30.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.